Sharief Group, the promoters of Allied Pharmacies, has posted a profit of £1.11 million in the 2024-25 financial year, as against a loss of £1.29m in 2023-24.
In its Companies House filing, published on January 3, the group claimed that for the year ended 31 March 2025, it maintained its service levels and continued to invest in digital transformation, workforce development, and patient safety, despite an "extremely challenging" environment.
The Merseyside-based pharmacy chain posted a 34 percent increase in its annual turnover to £128m, from £95.23m in the previous year, and its EBIDTA rose to £83m from £63m during the last year.
For its future, the group claimed that it continues to "pursue growth opportunities through acquisition and through strong relationships with its suppliers to generate a more efficient supply chain."
"The group's scale provides resilience in navigating the challenging funding environment that has affected smaller operators across the sector," it added.
The group said it was pursuing a strategy of selective growth "through the development of existing branches and the acquisition of branches with opportunities for synergy within the portfolio, while maintaining disciplined financial management."
It may be recalled that in late 2025, Allied Pharmacies had acquired the 129 branches of the troubled Jhoots Pharmacy in two batches in November (61 branches) and December (68 branches).
The group claimed its strategic Priorities for 2025/26 include maxımısıng income opportunities from the Pharmacy First scheme and expanding clinical services, leveraging digital investments to improve efficiency, integrate with NHS systems, and enhance patient care.
The group aims to manage ongoing cost pressures through operational excellence, efficient medicine sourcing, and prudent financial management.
